Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 31394942)

  • 1. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 2. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NADP
    Bian C; Zhang C; Luo T; Vyas A; Chen SH; Liu C; Kassab MA; Yang Y; Kong M; Yu X
    Nat Commun; 2019 Feb; 10(1):693. PubMed ID: 30741937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
    Hottiger MO
    Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of PARP as a successful target for cancer therapy.
    Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.
    Das PK; Matada GSP; Pal R; Maji L; Dhiwar PS; Manjushree BV; Viji MP
    Eur J Med Chem; 2024 Aug; 274():116535. PubMed ID: 38838546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors for anticancer therapy.
    Curtin N
    Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.